Ventyx Biosciences company info

What does Ventyx Biosciences do?
Ventyx Biosciences (NASDAQ:VTYX) is a biopharmaceutical entity focused on developing innovative therapies for autoimmune diseases and inflammatory disorders. The company is dedicated to advancing a pipeline of novel small molecule solutions designed to modulate key pathways involved in the immune response. Ventyx Biosciences aims to address unmet medical needs by bringing forth groundbreaking treatments that offer better safety, efficacy, and convenience for patients. With a commitment to scientific excellence and patient care, Ventyx Biosciences continues to seek out opportunities to expand its portfolio and impact lives positively through cutting-edge research and development efforts.
Ventyx Biosciences company media
Company Snapshot

Is Ventyx Biosciences a public or private company?

key
Ownership
Public

How many people does Ventyx Biosciences employ?

people
Employees
80

What sector is Ventyx Biosciences in?

pie chart
Sector
Health Care

Where is the head office for Ventyx Biosciences?

location pin
Head Office
California, United States

What year was Ventyx Biosciences founded?

founded flag
Year Founded
2018
What does Ventyx Biosciences specialise in?
/Biopharmaceutical Company /Immunotherapy Development /Anti-Body Therapeutics /Cancer Treatment /Drug Discovery /Research Services

What are the products and/or services of Ventyx Biosciences?

Overview of Ventyx Biosciences offerings
Development of selective TYK2 inhibitors for autoimmune and inflammatory diseases, offering a targeted approach in treating conditions like psoriasis and lupus.
Creation of a novel therapeutic for inflammatory bowel disease, focusing on a unique molecular target to provide relief for patients with this chronic condition.
Advancement of an oral small molecule drug targeting S1P1 receptors for the treatment of multiple sclerosis, aiming to provide an improved safety profile over existing therapies.
Development of therapies targeting the IL-17 pathway, focusing on innovative treatments for dermatological conditions.
Research into JAK inhibitors for the treatment of rheumatoid arthritis, aiming to offer more effective and less toxic options for patients.
Exploration of new treatments for alopecia, leveraging cutting-edge science to address hair loss with novel biological pathways.

Who is in the executive team of Ventyx Biosciences?

Ventyx Biosciences leadership team
  • Dr. Sheila K. Gujrathi M.D.
    Dr. Sheila K. Gujrathi M.D.
    Executive Chairperson
  • Dr. Raju S. Mohan Ph.D.
    Dr. Raju S. Mohan Ph.D.
    Founder, CEO, President & Director
  • Dr. John M. Nuss Ph.D.
    Dr. John M. Nuss Ph.D.
    Chief Scientific Officer
  • Dr. Martin Douglas Auster M.D.
    Dr. Martin Douglas Auster M.D.
    Chief Financial Officer
  • Mr. Christopher W. Krueger J.D., MBA
    Mr. Christopher W. Krueger J.D., MBA
    Chief Business Officer